Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2026-01-01 @ 3:34 PM
Study NCT ID:
NCT02866903
Status:
UNKNOWN
Last Update Posted:
2017-09-21
First Post:
2016-08-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis
Sponsor:
Hospices Civils de Lyon
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-05-18
Start Date Type:
ACTUAL
Primary Completion Date:
2019-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2019-03
Completion Date Type:
ESTIMATED
First Submit Date:
2016-08-04
First Submit QC Date:
None
Study First Post Date:
2016-08-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-09-20
Last Update Post Date:
2017-09-21
Last Update Post Date Type:
ACTUAL